Phase IV Trial Opens: Connected Platform vs Enhanced Care for CDK4/6 Inhibitor Adherence in Metastatic Breast Cancer — What Oncologists Need to Know

References

1. 1.ECOG-ACRIN Cancer Research Group. (2023). Improving Medication Adherence in Metastatic Breast Cancer Using a Connected Customized Treatment Platform (CONCURxP). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT06112613
2. 2.Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S. A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., Gauthier, E., Lu, D. R., Randolph, S., Diéras, V., & Slamon, D. J. (2016). Palbociclib and letrozole in advanced breast cancer. New England Journal of Medicine, 375(20), 1925-1936. https://doi.org/10.1056/NEJMoa1607303
3. 3.Greer, J. A., Amoyal, N., Nisotel, L., Fishbein, J. N., MacDonald, J., Stagl, J., Lennes, I., Temel, J. S., Safren, S. A., & Pirl, W. F. (2016). A systematic review of adherence to oral antineoplastic therapies. The Oncologist, 21(12), 1511-1519. https://doi.org/10.1634/theoncologist.2015-0405
4. 4.Spoelstra, S. L., Given, B. A., Given, C. W., Grant, M., Sikorskii, A., You, M., & Decker, V. (2013). An intervention to improve adherence and management of symptoms for patients prescribed oral chemotherapy agents. Cancer Nursing, 36(1), 18-28. https://doi.org/10.1097/NCC.0b013e31826fcdc2
5. 5.Hershman, D. L., Kushi, L. H., Shao, T., Buono, D., Kershenbaum, A., Tsai, W. Y., Fehrenbacher, L., Lin Gomez, S., Miles, S., & Neugut, A. I. (2010). Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. Journal of Clinical Oncology, 28(27), 4120-4128. https://doi.org/10.1200/JCO.2009.25.9655